Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium citrate Ga-67 is a diagnostic radiopharmaceutical agent used in nuclear medicine for Single-Photon Emission Computed Tomography (SPECT) imaging. When administered intravenously, gallium-67 behaves similarly to ferric iron (Fe3+) and binds to plasma proteins, primarily serotransferrin. The resulting gallium-transferrin complex circulates and preferentially accumulates in tissues with high metabolic activity, such as active inflammatory lesions and certain viable primary and metastatic tumors (including Hodgkin's disease, lymphomas, and bronchogenic carcinoma). This cellular uptake is mediated by transferrin receptors, which are highly expressed on rapidly dividing cancer cells and activated leukocytes. Once inside the cells, gallium concentrates in lysosomes and binds to intracellular proteins. The gamma radiation emitted by the decaying gallium-67 isotope is then detected by a gamma camera to produce scintigraphic images, aiding in the localization and evaluation of neoplastic and inflammatory pathologies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium (67Ga) citrate.